NCT02994784 · OUTCOME

Neutrophil Engraftment

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients · Source last updated 2023-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: 3 weeks

What was measured

time to neutrophil engraftment

Groups in this outcome

Evomela

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation Propylene Glycol-Free Melphalan Hydrochloride: Intravenous Propylene Glycol-Free Melphalan Hydrochloride

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Evomela	27

Reported measurements

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Evomela	10	Not reported	8	14	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
8
upper Limit
14
value
10

denoms

counts
group Id
OG000
value
27
units
Participants

description

time to neutrophil engraftment

dispersion Type

Full Range

groups

description
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation Propylene Glycol-Free Melphalan Hydrochloride: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
id
OG000
title
Evomela

param Type

MEDIAN

reporting Status

POSTED

time Frame

3 weeks

title

Neutrophil Engraftment

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice